Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NODAGA-SNA014 is an investigational radiopharmaceutical PET imaging agent developed by SmartNuclide Biopharma. It consists of a Claudin 18.2 (CLDN18.2)-targeting single-domain antibody (nanobody), SNA014, conjugated to a NODAGA chelator and radiolabeled with the positron-emitting isotope Gallium-68. CLDN18.2 is a tight-junction protein frequently overexpressed in gastrointestinal malignancies, including gastric and pancreatic cancers. The agent is designed for noninvasive quantification of CLDN18.2 expression via PET/CT imaging, serving as a companion diagnostic to identify patients likely to benefit from CLDN18.2-targeted therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-NODAGA-SNA014.